Our leadership team is made up of tenured healthcare, technology and life science executives and entrepreneurs. Results-oriented and mission driven, this diverse group is passionate about creating scalable care management solutions that enhance the relationship between patients and providers across all health populations.
Learn more about what makes MD Revolution different.
Parker spearheads MD Revolution's business development efforts, identifying the right sales and investor partnerships to drive business results. Throughout Parker's 40-year career, he has served in numerous leadership roles as an advocate to hospitals and provider organizations with IT strategies and operations. The MD Revolution family is fortunate to benefit from Parker’s visionary leadership.
In 2001, Parker founded maxIT Healthcare which quickly became the leading consulting practice providing IT solutions to healthcare provider organizations. MaxIT was the largest and fastest growing privately-held healthcare information technology firm in the industry prior to its acquisition by SAIC in 2012.
Parker founded Resources in Healthcare Innovations (RHI) in 1994, a healthcare IT consulting firm, where he served as CEO. With a strong commitment to developing a positive company culture, he grew RHI to a staff of 100+ employees and revenues of over $17 million within four years. In 1998, RHI merged with DAOU Systems, a publicly held IT consulting and management services firm. After the merger, he served as Senior Vice President of Sales, responsible for 450 employees and a $75 million operating budget. Earlier in his career Parker served the healthcare industry for several years as Interim/Contract CIO and Regional Vice President of Operations for a leading outsourcing firm. He has developed and implemented systems for Community Hospitals of Indianapolis.
Dr. Damani founded MD Revolution with the purpose of building the gold standard technology enabled service platform for physicians performing chronic care management. MD Revolution integrates patient generated data, electronic health records, and physician workflow for the purpose of optimizing population health management. He has served in multiple strategic and operational roles since the company’s founding and led efforts in raising over $43 million for the founding vision and now continues to lead efforts in product and clinical service development and corporate strategy.
In addition to his roles as Chief Medical and Strategy Officer, Dr. Damani remains highly active as an MD Revolution Board Member. He also serves as a Clinical Instructor in the Department of Family & Preventive Medicine for the UC San Diego Medical School and is a board-certified practicing cardiologist at Scripps Clinic – a top 20 US News and World Report heart care center.
Dr. Damani has also served as a scientific advisor for the prominent journal, Science Translational Medicine, and continues to serve as a reviewer for Nature Genetics, Annals of Internal Medicine, American Journal of Cardiology, and the Journal of the American College of Cardiology. In addition to his medical training, Dr. Damani has a Doctorate in Pharmacy from the University of Georgia and a Masters in Clinical Investigation from the Scripps Research Institute.
Jean leads MD Revolution’s information technology strategy, development, and organization. Experienced in and passionate about healthcare innovation, Jean is a force for change in technology, leading and driving a path of excellence in the MD Revolution’s software and technology solutions to redefine healthcare delivery.
As former CIO of large, complex healthcare organizations, at Scripps Health and Holy Cross Health System (now Trinity Health System), Jean is an established industry leader and arbiter of change. Jean designed and executed the strategic health IT plan for Scripps Health, a multi-hospital system including world-renowned Scripps Clinic. There she implemented an enterprise electronic health record (EHR), rebuilding Scripps’ IT architecture from the ground up.
With a PhD in Health Policy and Management, Jean serves on the faculty at UCLA Fielding School of Public Health. Jean authored Essentials of Health Information Systems and Technology, a textbook on health information systems and technology. She is founder of Bootstrap Incubation, LLC, a firm established to invest, mentor and grow life science and information technology start-ups.
Reese has a proven track record leading and scaling businesses. With tremendous healthcare, IT, and consulting expertise, Reese leads a customer centric approach to sales, implementation and customer onboarding processes.
Over the last ten years, he has led business units that have grown from 25% to 100% annually in revenue and profitability. Reese leads organizations that develop, market and deliver innovative information technology and professional service offerings to improve clinical, administrative and operational performance. Notably, as Executive Vice President of the Management Consulting Division at maxIT Healthcare, Reese achieved Best in KLAS® (2012) as a professional services firm in the healthcare provider electronic health record market and grew revenue from $5M to $60M in revenue during period 2010 to 2012.
Reese is committed to growing and fortifying an organization that will continue to set new benchmarks in patient outcomes with the RevUp care management platform. His leadership will establish MD Revolution as an industry recognized leader and patient/provider advocate.
Arthur is responsible for overseeing MD Revolution’s financial operations and is integral to the senior corporate development leadership team. Working closely with MD Revolution CEO Samir Damani, Arthur has supported raising over 30 million in capital from private and institutional investors.
He has helped build the organization’s infrastructure and manages high level company business. With his leadership, MD Revolution has grown its personnel and intellectual property assets.
Arthur has served in senior financial management roles in San Diego technology and biotechnology firms, including Chief Financial Officer at EMD Biosciences, Inc.; Chief Accounting Officer at Pharmacopeia Inc.; and VP of Finance at ProfitLine, Inc.
Ondrej leads the highly valued Analytics team, generating new insights from patient data that MD Revolution implements to improve the efficacy of RevUp, the company’s proprietary digital engagement platform. Ondrej is integral to strategic product development, maximizing RevUp’s direct improvement of patient health. The Analytics team is documenting groundbreaking results regarding statistically and clinically significant outcomes in engaged Medicare patients, particularly those with diabetes, obesity, and hypertension.
Prior to joining MD Revolution, Ondrej conducted research in computational biology and statistical genomics at The Scripps Research Institute in La Jolla, California. His research was published in numerous scientific reports in peer-reviewed journals including Science and Nature. Ondrej received his PhD in Bioinformatics from Charles University in Prague, Czech Republic.
Michael leads the MD Revolution Product Management group and is responsible for the product planning, user experience, design of our RevUp applications and management of platform services to support EMR integrations. He also leads the software development teams to maximize the effectiveness and efficiency of our technology efforts. Michael’s focus is on delivering an effective and engaging patient experience, providing product features to support our health care professionals and providing a seamless experience for our patients and providers.
Michael has extensive experience building and managing health and wellness technology products with a focus on creating engagement through data driven product decisions. He has developed products in a diverse range of sectors, including consumer health care, provider services, fitness, corporate wellness and consumer engagement. He has launched multiple internal applications to build efficiency in the delivery of services through effective use of technology. Most recently, he served as VP Product at Sharecare, Inc., where he managed products for their RealAge health assessment platform and products related to the exchange of medical records for patients and providers.
Pratik is exclusively focused on the Customer Experience. He is passionate about and dedicated to the highest standard of service and delivery to our providers and patients. With his oversight and enterprising guidance, Pratik ensures MD Revolution operates with brilliant effectiveness to extend and enhance the provider and patient experience.
As former COO, Pratik led core divisions of MD Revolution to operationalize vision, mission, values and practices. Pratik pioneered the development of MD Revolution's in-clinic processes and customer experience. Most notably, Pratik was the original manager of the development and production of RevUp—MD Revolution's digital healthcare platform. Pratik is responsible for fostering productive, ongoing relationships with MD Revolution customers. He is dedicated to creating and maintaining mutually beneficial business relationships with MD Revolution's strategic partners as well.
Prior to joining MD Revolution, Pratik spent 10 years working in private banking, consumer credit departments, and with investment professionals. He managed over $200 million in footings in a retail banking center, where he improved market share by 15% over four years, despite the recession. Due to his devotion to efficiency and customer service, these centers grew to a ranking of 3rd out of 170 branches nationwide. While the majority of Pratik's professional background lies in banking, he holds a BS in Psycho-biology and received his MD in 2001 with an emphasis in Physical Medicine and Rehabilitation.
As Medical Director of MD Revolution, Dr. Bhoyrul has revolutionized bariatric surgery using non invasive approaches pre and post operatively with the RevUp care management platform to maximize patient engagement and outcomes. He is dedicated to educating providers on the benefits of digital healthcare models and how they can be instrumental in driving outcomes in chronic care managed patient populations.
With his background and experience as a bariatric surgeon, Dr. Bhoyrul is uniquely positioned to understand and solve the needs of the multiple physician practices served by MD Revolution. He provides clinical guidance across the organization including designing and managing regulatory and clinical workflow processes for the Clinical Services division. Dr. Bhoyrul works directly with the Clinical and Analytics teams to optimize patient engagement methodologies leveraging real-time patient generated data.
Dr. Bhoyrul is Board certified, completing his surgical training in the UK, followed by a residency at Stanford University and a Fellowship in Advanced Laparoscopic Surgery at the University of California in San Francisco, and is currently Chief of Surgery at Scripps Memorial Hospital. He is extensively published and is co-editor of Fundamentals of Laparoscopic Surgery, one of the first textbooks in the field.
Gordon R. Clark is the founder and CEO of iProtean, LLC, an online information and education resource for CEOs and trustees of hospitals and health systems. He has also served as president and CEO of three private equity-backed firms and as board chair of another. His experience includes starting, acquiring, and selling companies. Prior to iProtean, Mr. Clark was the president and CEO of Learner's Digest International, the leading provider of Continuing Medical Education (CME) credits for physicians and web-based content management for medical and scientific societies. He was previously president and CEO of The Governance Institute, a firm serving the healthcare governance market. Before The Governance Institute, he led First American Records Management, a records and information management company headquartered in Silicon Valley. He is a graduate of Cornell University and the Fordham University Graduate School of Business. Mr. Clark currently serves as chairman of the Scripps Health Board of Trustees.
Jean has served for more than 20 years as CIO of large, complex health care organizations, working for such health systems as Scripps Health and Holy Cross Health System (now Trinity Health System). For the past six years she has also served as health IT educator at UCLA Fielding School of Public Health. With many years of experience leading and implementing system initiatives, Jean prides herself on being able to think of ways to use IT to advance the vision and strategies of an organization, as well as help it become more efficient and effective. She is responsible for designing and carrying out the strategic HIT plan for Scripps Health, a multi-hospital system including world-renowned Scripps Clinic, and implementing an enterprise electronic health record (EHR). Currently, Jean is completing her PhD in Health Policy and Management. She has written a textbook on health information systems and technology due to be published in the summer of 2014. She is founder of Bootstrap Incubation, LLC, a firm established to invest in and provide mentorship and services to life sciences and information technology start-ups.
Dr Damani is the MD Revolution Founder and CEO, as well as a recognized change agent in healthcare.
With a group of experienced healthcare and technology leaders, he is blazing a trail in the rapidly changing healthcare market by empowering patients and providers to focus on “health” care and away from episodic illness care. He has provided excellence in chronic care management through innovative approaches to patient engagement and remote care delivery. Today, MD Revolution’s chronic care management solution has been implemented across small and large provider group settings for thousands of patients, and has enabled value based care and new revenue streams for physicians across the nation.
Under his leadership, his clinical team and data scientists have demonstrated outstanding clinical outcomes in patients by digitizing a data driven and highly personalized healthcare experience. He has also led the efforts in building the scalable, secure, and proprietary patient engagement technology platform – RevUp. RevUp is the only chronic care management tool with proven capabilities for new clinical knowledge creation via machine learning, while also providing highly secure messaging capabilities via a remote clinical care team.
In addition to leading the company’s day to day operations and having raised over $30 million in financing for MD Revolution’s trailblazing efforts, Dr. Damani has directed numerous studies, including one on biomarkers of heart attacks sponsored by the National Institutes of Health. He has also written over 40 articles and book chapters, and has spoken at national and international forums on personalized medicine, genomics, digital health, and wellness.
He has served as a scientific advisor for the prominent journal, Science Translational Medicine, and continues to serve as a reviewer for Nature Genetics, Annals of Internal Medicine, American Journal of Cardiology, and the Journal of the American College of Cardiology. Samir also serves as a Clinical Instructor in the Department of Family & Preventive Medicine for the UC San Diego Medical School and is a board-certified practicing cardiologist at the top 20 US News and World Report heart care center, Scripps Clinic, in San Diego.
Dr. Kosecoff is currently working in private equity to identify, select, mentor and manage health services and IT companies. From 2002-2012, Dr. Kosecoff was a senior executive inside UnitedHealth Group-PacifiCare. At PacifiCare, Dr. Kosecoff served as Executive Vice President with responsibility for its specialty businesses, including its PBM, the Medicare Part D Drug Program, Behavioral Health, Dental & Vision, and Women’s Health Solutions. In 2005, United acquired PacifiCare. At United, Dr. Kosecoff was CEO of OptumRx with responsibility for United’s PBM, Specialty Pharmacy and Consumer Health Products, providing services to more than 13 million members with annual revenue of $18.5 billion. Prior to joining UnitedHealth Group-PacifiCare, Dr. Kosecoff was founder and President of Protocare, and co-founder and Co-CEO of Value Health Sciences. Dr. Kosecoff began her career as a Professor of Medicine and Public Health at the University of California, Los Angeles. She has served as a consultant to the World Health Organization’s Global Quality Assessment Programs, on the Institute of Medicine’s Board of Health Care Services, and the RAND Graduate School’s Board of Governors.
Currently, Dr. Kosecoff sits on the board of directors of these public companies: athenahealth, Inc. (NASDAQ: ATHN); Sealed Air Corporation (NYSE: SEE); and, STERIS Corporation (NYSE: STE) and these private companies: DJO Global, Inc.; Independent Living Systems, LLC; MD Revolution Inc.; and, Specialists on Call, Chairman. She is also a member of the Executive Advisory Board of SAP America Inc. (NYSE: SAP).
Dr. Kosecoff holds a BA from the University of California, Los Angeles (UCLA), an MS in Applied Mathematics from Brown University, and a doctorate from UCLA.
Garrett is a physician entrepreneur and healthcare investor with over 15 years of experience in medtech, HCIT, digital health, biotech and diagnostics. He leads the Health Care Practice at Jump Capital.
He received his Medical Degree and MBA from Georgetown University and completed his clinical training at the University of Pennsylvania. Garrett left full time practice and academics to join Genentech for the launch of Lucentis™, a $4B therapeutic franchise for the treatment of age related macular degeneration.
From Genentech, Garrett was a Director at Burrill Venture Capital group where he led investments in biotech, medtech, specialty pharma and health care IT companies. He founded NewBridge Pharmaceuticals, a Dubai-based specialty pharmaceutical company focused on the emerging markets. During his tenure, the company grew to 100+ employees, raised over $65 million in financing and created $470 million in nominal value. He served on the Board, recruited key management professionals and led corporate development, strategy and partnership opportunities.
Garrett has served on a wide variety of corporate and non-profit boards in his career. He is a frequent lecturer at UCSF and is Kauffman Fellow of Class 13.
Co-Founder & CEO Althea Dx; Founder, Althea Technologies
Dr. Ferré is Co-Founder & CEO of Althea Dx, a spin-off of Althea Technologies focusing on the development of companion diagnostics. Prior to Althea Dx, Dr. Ferré co-founded Althea Technologies, Inc. and served as co-CEO from 1998-2008. He has over twenty years of experience in cancer research and HIV clinical development. Dr. Ferré has held management positions at Cytometrics and The Immune Response Corporation. He is a leader in gene quantification and biomarker development with over fifteen years of experience in the field. He has published several authoritative reviews on the topic of gene quantification, co-edited a bestselling book on PCR with Dr. Kary Mullis and Dr. Richard Gibbs, and edited a book on the topic of gene quantification. Dr. Ferré received his Ph.D. in Molecular Oncology from the Pasteur Institute in Lille, France and did his post-doctoral training at the University of California, San Diego. Dr. Ferré was the recipient of the 2005 Ernst & Young Entrepreneur of the Year award in the Life Sciences category.
President & CEO, Ajinomoto Althea
Dr. Marquet is founder and co-Chair of Althea Technologies, and served as its co-President and CEO for ten years. Dr. Marquet is also founder and co-Chair of Althea Dx, a spin-off of Althea Technologies focusing on companion diagnostics development. Dr. Marquet has over twenty-five years of experience in the biotechnology industry in the United States and Europe. She was formerly Executive Director of Pharmaceutical Development at Vical Incorporated, where she patented several novel methods for the production of clinical grade DNA for use in gene therapy and DNA vaccines. Prior to joining Vical, Dr. Marquet held management positions at Amylin Pharmaceuticals, Protein Polymer Technologies, Syntro Corporation and Transgene. Dr. Marquet is a member of the board of Directors of BIOCOM. Dr. Marquet holds a Ph.D in Biochemical Engineering from INSA/University of Toulouse, France. Dr. Marquet has received numerous awards throughout her career. She was the winner of the 2005 Regional Ernst & Young Entrepreneur of the Year award in the Life Sciences category. While leading Althea Technologies, she received several Best Companies to Work For awards from the San Diego Business Journal.
Dan Bradbury is a Life Sciences Executive with over 30 years of experience creating and implementing strategies that transform businesses, bring novel medicines to market and maximize shareholder value. He is the Managing Member of BioBrit, LLC, a Life Sciences Consulting and Investment Firm. Dan is the former President, Chief Executive Officer and Director of Amylin Pharmaceuticals, a biopharmaceutical company based in San Diego, CA, focused on metabolic diseases. During his 18-year tenure at Amylin, the company launched three first-in-class medicines, including the first once-a-week therapy to treat diabetes, and was listed on the Nasdaq 100. He served as Amylin's Chief Executive Officer from March 2007 until its acquisition by Bristol-Myers Squibb Company for $7 billion in August 2012. Before joining Amylin, Dan worked in marketing and sales roles for ten years at SmithKline Beecham Pharmaceuticals. He serves on the board of directors of Corcept Therapeutics (NASDAQ: CORT), Geron Corporation (NASDAQ: GERN), Illumina, Inc. (NASDAQ: ILMN), BioMed Realty (NYSE: BMR), Microdermis, Inc. (Private) and Castle Biosciences, Inc. (Private). He also serves on the board of trustees of the Keck Graduate Institute, the Investor Growth Capital Advisory Board and the BioMed Ventures Advisory Committee. Dan currently serves on the University of California San Diego's Rady School of Management's Advisory Council and the University of Miami's Innovation Corporate Advisory Council. He received a Bachelor of Pharmacy from Nottingham University and a Diploma in Management Studies from Harrow and Ealing Colleges of Higher Education in the United Kingdom.
Dave Dowling is the Founder and Managing Principal of Aligns, Inc., and provides strategy and organizational/leadership development services to a wide range of clients in healthcare. He is also a member of the Executive Advisory Board of Union Village, the world’s first integrated senior healthcare community being built in Henderson Nevada, and serves on the Advisory Board of Branch2, a digital behavioral health company.
He has held executive leadership roles in health care, financial services and technology businesses where he led numerous business and organizational strategy initiatives. He has held senior roles in strategy, business development, learning and human resources at Aetna, Pitney Bowes, and United Technologies, MassMutual and Travelers.
Over the past fifteen years his clients have included Stamford University Health System, Ascension Health, Fidelity, HCA, Pfizer, Catamaran, Anthem, University of Wisconsin School of Business, Health Care Service Corporation, and numerous early to mid-stage private equity backed healthcare and technology companies.
Dave earned a BS degree from Central Connecticut State University and a MS degree from University of Bridgeport. He also pursued additional graduate studies at The Juilliard School, and Wesleyan University, as well as business studies at the University of Pittsburg and Wharton.
He divides his time between consulting/advising the C-Suite and business development support for early stage companies, so that he has time to for volunteer work.
Joseph C. Kvedar, MD, Founder and Vice President of the Center for Connected Health, Partners HealthCare, is creating a new model of healthcare delivery, developing innovative strategies to move care from the hospital or doctor’s office into the day-to-day lives of patients.
Dr. Kvedar is leveraging information technology – cell phones, computers, networked devices and remote health monitoring tools – to improve care delivery. Based on the technology platform developed at the Center, a personalized health technology company was launched and later acquired by a leading insurance company to support its program encouraging healthy behavior and wellness education among employee populations. Dr. Kvedar also established the first physician-to-physician online consultation service in an academic setting, linking patients from around the world with specialists at Harvard-affiliated teaching hospitals.
He is internationally recognized for his leadership and vision in the field of connected health, and has authored over 90 publications on the subject. Dr. Kvedar serves as a strategic advisor at Qualcomm Life, West Health Institute, Puretech Ventures and BD Technologies, and is a mentor at Blueprint Health, providing guidance and insight to developing companies. Dr. Kvedar is also a judge for the President's Challenge for Entrepreneurship hosted by the Harvard Innovation Lab.
In addition to serving on MD Revolution's Advisory Board, Rafael Pastor serves on the Boards or Advisory Boards of various companies, including eDisability Quotes, Boost Academy, RosettaBooks, Thuzio, and Vistage International. He also serves as an advisor to a major international private equity firm, as well as on the Board of the La Jolla Music Society, the Advisory Board of the Rady School of Management at UCSD, and the Strategic Roundtable of the San Diego Economic Development Corporation. Previously, he was Chairman of the Board and CEO of Vistage International, the world's largest for-profit CEO-development membership company, with over 17,000 members in 15 countries. After running and growing Vistage from 2004-13, he managed its sale to two private equity firms, "rolled" a portion of his realized gain to join the new investors in the company, and remains a member of Vistage's Board of Directors. Prior to joining Vistage, Pastor had an extensive background in both leading and advising business enterprises. Based in New York, he held senior executive positions at global media companies as: CEO of Hoyts Cinemas Corporation; President of USA Networks International; Executive Vice President, International, of News Corporation and Fox Television; and President of CBS/Fox Video International. In these positions, he dealt with all aspects of the film, television and publishing businesses in the United States and throughout the world. Subsequently, he co-founded the Sonenshine Pastor (now Sonenshine Partners) investment-banking and venture-capital firm in New York City. Pastor started his career as an attorney, first at the Wall Street law firm of Hawkins, Delafield and Wood and then as Associate General Counsel at CBS Inc. He earned a BA from Columbia University and a JD from NYU School of Law. He has worked and traveled extensively abroad, and speaks several languages. In addition to his broad experiences as a Board member, Pastor has participated in Board meetings and deliberations as a CEO, investment banker, and attorney.
Mr. Andrew Sassine served in various positions at Fidelity Investments from 1999 to 2012, rising to the position of Portfolio Manager. During his tenure, Mr. Sassine managed the Fidelity Small Cap Stock Fund, the Fidelity International Small Cap Opportunities Fund and the Fidelity Advisor International Small Cap Opportunities Fund. Mr. Sassine started his career at Fidelity as a high yield research analyst covering the Telecommunications, Satellite, Technology, Defense and Aerospace, and Restaurant Industries and in 2001, joined the international group as a research analyst covering small and mid-cap international stocks. Prior to joining Fidelity, he served as a vice president in the Acquisition Finance Group at Fleet National Bank.
Mr. Sassine serves on the board of directors of two public companies: FluoroPharma Medical, Inc., (FMPI.OB), a bio pharmaceutical company focusing on the development of positron emission tomography imaging agents for the detection and assessment of acute and chronic forms of coronary artery diseases; and CNS Response, Inc. (CNSO.OB), a clinical decision support company providing reference data and analytical tools for clinicians and researchers in psychiatry. Mr. Sassine also serves on the board of directors of four private companies: Gemphire Therapeutics Inc., an early-stage cardiovascular drug company focused on lowering LDL (bad cholesterol) and triglycerides; MD Revolution Inc., a digital health service company focused on leveraging genomics and mobile health technology to predict, prevent and reverse chronic disease and lower healthcare costs; Freedom Meditech, Inc., a medical device company focused on the development and commercialization of first-to-market non-invasive ophthalmic medical devices that can screen for diabetes up to six years prior to the onset of the disease; and ComHear Inc., a digital audio software and device company, where he is also the Chairman of the Board.
Mr. Sassine has been a member of the Henry B. Tippie College of Business, University of Iowa Board of Advisors since 2009 and served on the Board of Trustees at the Clarke Schools for Hearing and Speech from 2009 through 2014. Mr. Sassine earned a Bachelor of Arts degree at the University of Iowa in 1987 and an MBA from the Wharton School at the University of Pennsylvania in 1993.
Director of Bioinformatics and Biostatistics, Scripps Translational Science Institute Professor, Department of Molecular and Experimental Medicine, The Scripps Research Institute
Professor of Psychiatry and Biostatistics (adjunct), UC San Diego
Nicholas J. Schork, Ph.D., is a Professor at the Scripps Research Institute in the Department of Molecular and Experimental Medicine and Director of Bioinformatics and Biostatistics at the Scripps Translational Science Institute. Dr. Schork's interests and expertise are in quantitative human genetics and integrated approaches to complex biological and medical problems, especially the design and implementation of methodologies to identify the determinants of complex traits and diseases. He has published over 350 scientific articles and book chapters on the analysis of complex, multifactorial traits and diseases. Prior to joining Scripps in 2007, Dr. Schork was a Professor of Biostatistics and Psychiatry, and Co-Director of the Center for Human Genetics and Genomics, at the University of California, San Diego. From 1994 to 2000, he was an Associate Professor of Epidemiology and Biostatistics at Case Western Reserve University and an Adjunct Associate Professor of Biostatistics at Harvard University. From 1999 to 2000, Dr. Schork took a leave of absence to conduct research as the Vice President of Statistical Genomics at the French biotechnology company, Genset. While there, he helped guide efforts to construct the first high-density DNA sequence variation map of the human genome. As a member of several scientific journal editorial boards, Dr. Schork is a frequent participant in U.S. National Institutes of Health’s (NIH) steering committees and review boards. He is a frequent scientific lecturer, graduate educator, and mentor, and has served on the advisory board of five companies, in addition to being the director of the quantitative components of a number of national research consortia, including the NIA-sponsored Longevity Consortium and the NIMH-sponsored Bipolar Consortium. Dr. Schork earned a B.A. in Philosophy, an M.A. in Philosophy, an M.A. in Applied Statistics, and a Ph.D. in Epidemiology, all from the University of Michigan in Ann Arbor.
Founding Director, California Institute for Telecommunications and Information Technology
Larry Smarr is the founding Director of the California Institute for Telecommunications and Information Technology (Calit2), a University of California, San Diego (UCSD) and UC Irvine partnership created in 2000. He holds the Harry E. Gruber professorship in the Jacobs School's Department of Computer Science and Engineering at UCSD. At Calit2, Smarr continues to drive major developments in planetary information infrastructure which began during his 15 years as founding Director of the National Center for Supercomputing Applications and the National Computational Science Alliance. These developments include major contributions to the Internet, the Web, scientific visualization, virtual reality, collaboratories, global telepresence and Green IT. His views have been quoted in Science, Nature, the New York Times, Wall Street Journal, Time, Newsweek, Wired, Fortune, Business Week, the Sydney Morning Herald, The Age, and the Australian Broadcasting Company. Smarr was Principal Investigator (PI) on the NSF OptIPuter project (2002-2009) and is currently PI on the Moore Foundation's CAMERA microbial metagenomics project. Smarr was a member of President Clinton's Information Technology Advisory Committee and served until 2005 on the Advisory Committee to the Director of the National Institutes of Health. He has served four NASA Administrators as a member of the NASA Advisory Council. He is currently chair of the National Science Foundation's Advisory Committee for Cyberinfrastructure. He served on Governor Schwarzenegger's California Broadband Taskforce in 2007. Smarr received his Ph.D. from the University of Texas at Austin in 1975 and conducted observational, theoretical, and computational-based astrophysical sciences research for the 20 years. He is a member of the National Academy of Engineering and a Fellow of the American Physical Society and the American Academy of Arts and Sciences. In 1990, he received the Franklin Institute's Delmer S. Fahrney Gold Medal for Leadership in Science or Technology. In 2006, he received two Lifetime Achievement awards: the IEEE Computer Society Tsutomu Kanai Award in distributed computing systems and the ESRI Award.
Principal, FD Stonewater
David brings 15 years of principal-ownership and advisory experience from both the real estate investment-banking arena and as a co-founder and manager of a successful real estate investment firm. At FD Stonewater, David's vast expertise and leadership is highly valued in their investment, asset management, corporate services, investment- banking, and development platforms.
Managing Director & Global Healthcare Innovation Leader, PWC
Chris Wasden is a Managing Director and the Global Healthcare Innovation Leader at PwC . Prior to PwC, he led nine startups, which included corporate ventures, venture financed startups, incubators, and family owned businesses. He is a named inventor on 20 issued and pending patents. He has authored over 20 reports and papers on innovation that have outlined his philosophy and approach for successful innovation. His Innovation Cycle, which is based upon Chaos Theory and NeuroScience, indicates that a failure to innovate is a failure of leadership and describes how leadership must harness social tensions to drive and enable the innovation throughout their entire organization. He leads innovation engagements with large and small organizations to help leadership enable transformational change that gets innovation into the DNA of the culture and thereby drive greater growth and success on a sustainable basis. Dr. Wasden has a doctorate in human and organizational learning from George Washington University in Washington, DC, an MBA from the UCLA Anderson School, and a bachelor's degree in accounting and Asian studies from Brigham Young University in Provo, Utah.